ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK signaling is only beneficial to a small subset of patients due to resistance that arises through genetic, transcriptional, and metabolic adaptation. Identification of targetable vulnerabilities in NRAS-mutated melano...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2023-04, Vol.83 (7), p.1128-1146
Hauptverfasser:	Eichhoff, Ossia M, Stoffel, Corinne I, Käsler, Jan, Briker, Luzia, Turko, Patrick, Karsai, Gergely, Zila, Nina, Paulitschke, Verena, Cheng, Phil F, Leitner, Alexander, Bileck, Andrea, Zamboni, Nicola, Irmisch, Anja, Balazs, Zsolt, Tastanova, Aizhan, Pascoal, Susana, Johansen, Pål, Wegmann, Rebekka, Mena, Julien, Othman, Alaa, Viswanathan, Vasanthi S, Wenzina, Judith, Aloia, Andrea, Saltari, Annalisa, Dzung, Andreas, Krauthammer, Michael, Schreiber, Stuart L, Hornemann, Thorsten, Distel, Martin, Snijder, Berend, Dummer, Reinhard, Levesque, Mitchell P
Format:	Artikel
Sprache:	eng
Schlagworte:	Cell Line, Tumor GTP Phosphohydrolases - genetics Humans Melanoma - drug therapy Melanoma - genetics Melanoma - pathology Membrane Proteins - genetics Mitogen-Activated Protein Kinase Kinases - genetics Mutation Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins B-raf - genetics Reactive Oxygen Species Skin Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!